Amid Declining Revenues, Illumina Plans to Restructure, Focus on Clinical Market | GenomeWeb

By Monica Heger

Illumina is planning a restructuring that will include "the creation of a new business unit that will be focused specifically on the clinical markets," CEO Jay Flatley said during a conference call to discuss the company's third-quarter results today.

Illumina will begin implementing its restructuring plan "shortly," Flatley said, but did not elaborate other than to say that the company will provide further details "soon."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.